Context Therapeutics (Context Therapeutics) Float Percentage Of Total Shares Outstanding : 98.55% (As of May. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Context Therapeutics's float shares is 73.91 Mil. Context Therapeutics's total shares outstanding is 75.00 Mil. Context Therapeutics's float percentage of total shares outstanding is 98.55%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Context Therapeutics's Insider Ownership is 1.92%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Context Therapeutics's Institutional Ownership is 10.60%.

Context Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Context Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	73.91	/	75.00
	=	98.55%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics (Context Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Executives

Martin A. Lehr	director, officer: Chief Executive Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary	officer: Chief Financial Officer	110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit	officer: Chief Legal Officer, Corp. Sec	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud	officer: Chief Medical Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey	director	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick	officer: SVP of R&D	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher	officer: Head of CMC and Regulatory	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104